US2014243379A1PendingUtilityA1
Adhesive mixture for transdermal delivery of highly plasticizing drugs
Est. expiryJun 26, 2017(expired)· nominal 20-yr term from priority
A61K 45/06A61K 9/7061A61K 47/32A61K 31/137A61K 31/138A61K 31/4402
73
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
Claims
exact text as granted — not AI-modified1 . A transdermal delivery system comprising a blend of
(a) one or more hydrophobic adhesive polymers; (b) a therapeutically effective amount of one or more drugs, at least one of which is of low molecular weight and liquid at or about room temperature; and (c) a solvent system including at least one solvent, said solvent system being free of low volatility solvents, said low volatility solvents comprising solvents which are not volatilized at temperatures of from about 100° F. to 200° F.
2 . The transdermal delivery system of claim 1 wherein said one or more drugs comprise one or more highly plasticizing drugs.
3 . The transdermal delivery system of claim 2 wherein said highly plasticizing drugs are selected from the group consisting of selegiline, fluoxetine, des-methyl selegiline, tetracaine and chlorpheniramine.
4 . The transdermal delivery system of claim 1 wherein said one or more hydrophobic adhesive polymers comprise one or more acrylic polymers.
5 . The transdermal delivery system of claim 1 including from about 3% to 35% by weight of said therapeutically effective amount of one or more drugs.
6 . The transdermal delivery system of claim 3 wherein said highly plasticizing drug comprises selegiline.
7 . The transdermal delivery system of claim 6 including from about 3% to 18% by weight of said selegiline.
8 . A transdermal delivery system comprising a blend of
(a) one or more hydrophobic acrylic adhesive polymers and one or more secondary adhesive polymers; (b) a therapeutically effective amount of one or more drugs, at least one of which is of low molecular weight and liquid at or about room temperature; and (c) a solvent system including at least one solvent, said solvent system being free of low volatility solvents, said low volatility solvents comprising solvents which are not volatilized at temperatures of from about 100° F. to 200° F.
9 . The transdermal delivery system of claim 8 wherein said one or more secondary adhesive polymers is selected from the group consisting of silicones, polyisoalkylenes, rubbers, vinyl acetates, polyisobutylenes, polybutadiene, styrene-butadiene (or isoprene)-styrene block copolymer rubber, acrylic rubber, natural rubber, vinyl-based high molecular weight materials, polyvinyl acetate, polyvinyl alcohol, polyvinyl pyrrolidone; cellulose derivatives, polysaccharides, polyurethane elastomers and polyester elastomers.
10 . The transdermal delivery system of claim 9 wherein said one or more secondary adhesive polymers are selected from the group consisting of polyisobutylenes and silicones.
11 . The transdermal delivery system of claim 9 including from about 65% to 97% by weight of said one or more hydrophobic acrylic adhesive polymers.
12 . The transdermal delivery system of claim 11 wherein said one or more hydrophobic acrylic polymeric adhesive polymers includes between about 40% and about 90% of a C 4 -C 12 alkyl acrylate, between about 10% and about 40% by weight of a C 1 -C 3 alkyl acrylate hardening monomer.
13 . The transdermal delivery system of claim 11 including between about 1% and about 20% by weight of a monomer which provides functional groups for crosslinking and a crosslinking agent.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.